Literature DB >> 11356074

Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina.

L H McGee Sanftner1, K G Rendahl, D Quiroz, M Coyne, M Ladner, W C Manning, J G Flannery.   

Abstract

Viral delivery of neurotrophins or other therapeutic genes is an attractive option for treating retinal degeneration. Regulated expression of these genes in the retina is needed to aid in dose delivery and to promote safety. To evaluate whether tetracycline (tet)-inducible transgenes encapsidated in recombinant adeno-associated viruses (rAAV) can provide controlled gene expression in vitro and in the rat retina, two viruses were constructed: a silencer/activator vector and an inducible doxycycline (dox)-responsive GFP vector. Combinations of these two viruses were subretinally injected into wild-type rats and dox was orally administered through the drinking water. Retinal GFP expression was monitored in vivo with a noninvasive fluorescence imaging method. Eyes were also examined by histology, Western analysis, and electroretinography. Subretinal injection of rAAV efficiently delivers inducible genes to both photoreceptors and retinal pigment epithelial cells. GFP expression was initially observed 1 week postinduction, and GFP protein was undetectable after removal of dox. In uninduced animals, GFP expression was negligible. The dox dosage was varied in vivo and showed a correlation to the level of GFP expression. Thus, transduction of retinal cells with tet-inducible vectors allows for tight regulation of gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356074     DOI: 10.1006/mthe.2001.0308

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  19 in total

1.  Viral-mediated FGF-2 treatment of the constant light damage model of photoreceptor degeneration.

Authors:  Dana Lau; John Flannery
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

2.  Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin.

Authors:  Zetang Wu; Marina Mata; David J Fink
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 3.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 4.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

Review 5.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

6.  Regulation of episomal gene expression by KRAB/KAP1-mediated histone modifications.

Authors:  Isabelle Barde; Elisa Laurenti; Sonia Verp; Anna Claire Groner; Christopher Towne; Viviane Padrun; Patrick Aebischer; Andreas Trumpp; Didier Trono
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

7.  Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors.

Authors:  Elsa Lhériteau; Lyse Libeau; Alexandra Mendes-Madeira; Jack-Yves Deschamps; Michel Weber; Guylène Le Meur; Nathalie Provost; Caroline Guihal; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2010-03-30       Impact factor: 11.454

8.  PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer.

Authors:  Sai K Saridey; Li Liu; Joseph E Doherty; Aparna Kaja; Daniel L Galvan; Bradley S Fletcher; Matthew H Wilson
Journal:  Mol Ther       Date:  2009-10-06       Impact factor: 11.454

9.  Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer.

Authors:  Lucia Vanrell; Marianna Di Scala; Laura Blanco; Itziar Otano; Irene Gil-Farina; Victor Baldim; Astrid Paneda; Pedro Berraondo; Stuart G Beattie; Abdelwahed Chtarto; Lilianne Tenenbaum; Jesús Prieto; Gloria Gonzalez-Aseguinolaza
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

10.  A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.

Authors:  Clayton P Santiago; Casey J Keuthan; Sanford L Boye; Shannon E Boye; Aisha A Imam; John D Ash
Journal:  Mol Ther       Date:  2018-07-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.